Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in CD30-positive Nonlymphomatous Malignancies
NCT01461538Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Oct 2011
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in Solid tumors, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), testicular cancer, mesothelioma, sponsored by Seagen Inc.. Started Oct 2011; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Solid tumorsacute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)testicular cancermesothelioma
Beyond the preview
Go deeper on NCT01461538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01461538.